Roche, one of the largest biotech companies, continues to expand its late-stage drug pipeline through focused acquisitions and regulatory milestones. In recent Roche news, the company will acquire liver drug developer 89bio for up to $3.5 billion.
Alongside the acquisition, Roche secured a CE mark for Contivue, its port delivery platform.
Roche News: Roche to Acquire 89bio for $3.5 Billion
Roche announced on September 18 that it will acquire 89bio in a transaction valued at up to $3.5 billion.
[#MEDIA] Excited to announce that we entered into a definitive merger agreement with 89bio, a key step in tackling Metabolic Dysfunction-Associated Steatohepatitis (MASH), a serious liver disease linked to obesity. This move enhances our CVRM portfolio and deepens our commitment… pic.twitter.com/l8YQgYHOsS
— Roche (@Roche) September 18, 2025
This agreement includes a $14.50 per share cash payment at closing, giving the deal an upfront equity value of approximately $2.4 billion.
In addition, the terms include a contingent value right (CVR) of up to $6.00 per share.
At the same time, the acquisition strengthens Roche’s pipeline in cardiovascular, renal, and metabolic diseases (CVRM).
It also broadens its future development options, particularly for combination therapies in overlapping chronic conditions.
Roche News: Roche Gains CE Mark for Susvimo-Enabled Contivue
In other Roche news, Roche announced on September 4 that it received the EU CE mark for Contivue.
We’re pleased to share that our port delivery platform has received CE mark approval in Europe. This marks a significant step in advancing treatment for nAMD, the leading cause of vision loss in people over 60. https://t.co/1oMLbnqRpd pic.twitter.com/washzKPw9u
— Roche (@Roche) September 4, 2025
In Europe, the platform will be Contivue and includes five components: the implant itself and four ancillary devices used for initial fill, insertion, refill, and removal if needed.
Contivue is designed for continuous delivery of a custom formulation of ranibizumab (100 mg/mL). This is under EMA review for treating neovascular age-related macular degeneration (nAMD).
The system releases the drug gradually, offering longer-lasting results without frequent injections.
Additionally, the platform is built specifically around ranibizumab’s molecular profile to ensure stable, consistent drug release into the eye.
Roche also plans to test other compounds with the system, which could extend its use beyond nAMD into other retinal diseases.
Conclusion
Roche’s recent moves reflect a capital deployment strategy prioritizing assets with near-term impact and longer-term optionality.
Its ongoing investments in specialized delivery platforms and targeted treatments support future revenue diversification, particularly as biosimilar pressure and patent expirations continue to affect legacy assets.
As a result, Roche appears to be positioning itself for stability in a slower-growth environment, focusing on high-value assets rather than volume-driven plays.
For ongoing coverage of Roche news and deeper financial insights, subscribe to Financial Daily Update today.
Latest News
-
Groq: $6.9B Valuation and HUMAIN Partnership
-
Rithm Capital: Paramount Deal, Crestline Acquisition & Loan Securitization
-
Databricks News: Indicium Stake, AI Growth Milestone, & Series K Funding
-
Workday: Elliot Stake, Sana Acquisition & Microsoft Collaboration
-
Cohere AI: Paris Office Launch and $6.8B Valuation
-
Tether News: US Stablecoin Launch, Legacy Blockchain Plans
-
Lendbuzz: IPO Filing, Revenue Surge & $266M Securitization
